Skip to content

Study · Animal study (in vivo) · 2010

4 results

Identification of Thymosin β4 as an effector of Hand1-mediated vascular development.

Smart N, Dubé KN, Riley PR

Nature communications27 Jul 2010Cited by 34 (Europe PMC)

PMID20975697 (opens in a new tab)DOI10.1038/ncomms1041 (opens in a new tab)PepBankPUB-20975697
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Hand1-null embryos, administration of synthetic TB4 partially rescued yolk sac capillary plexus formation.

    In plain wordsIn embryos lacking Hand1, synthetic thymosin beta‑4 partly restored the growth of yolk sac blood vessels.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseYolk sac capillary plexus formation
    Study

    n: not reported in source

    Hand1-null embryos
    Outcome group
    Angiogenesis · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    administration of synthetic TB4 partially rescues yolk sac capillary plexus formation in Hand1-null embryos.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    Hand1-mediated activation of Tbeta4 was essential for yolk sac vasculogenesis and embryonic survival.

    In plain wordsIn embryos, the body's own thymosin beta‑4, switched on by Hand1, was needed for yolk sac vessel formation and embryo survival.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableHand1-mediated activation of Tbeta4 in yolk sac vasculogenesis and embryonic survival
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Hand1-mediated activation of Tβ4 is essential for yolk sac vasculogenesis and embryonic survival

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 03LabEndogenous levelOther designMechanism

    Hand1 binds an upstream regulatory region proximal to the promoter of the Tbeta4 gene at consensus Thing1 and E-Box sites.

    In plain wordsIn lab tests, the Hand1 protein attaches to a control region of the gene for the body's own thymosin beta‑4.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableHand1 binding to the Tbeta4 regulatory region
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    Hand1 binds an upstream regulatory region proximal to the promoter of Tβ4 at consensus Thing1 and E-Box sites

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 04LabEndogenous levelOther designMechanism

    Hand1 both activated and repressed Tbeta4 through direct binding within non-canonical or canonical E-boxes.

    In plain wordsIn lab tests, the Hand1 protein both raised and lowered the body's own thymosin beta‑4 gene activity.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    MixedHand1 regulation of Tbeta4 expression
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    identify both activation and repression of Tβ4 by Hand1, through direct binding within either non-canonical or canonical E-boxes

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.